The Priority Review Voucher Program is intended to encourage development of therapies to prevent and treat rare pediatric diseases.
If LBS-008 is approved by the FDA for Stargardt Disease, the RPD designation qualifies Lin BioScience for the Priority Review Voucher.
The voucher, which can be sold or transferred to another entity, can be used by the sponsor to receive Priority Review for a future NDA or BLA submission and reduce the candidate's FDA review time to six months.
LBS-008 is a first-in-class oral therapy that prevents the buildup of toxins in the eye that cause Stargardt Disease and atrophic Age-related Macular Degeneration (dry AMD).
The NIH's Blueprint Neurotherapeutics Network, which funded the therapy's discovery and development, provides support and funding through to the completion of Phase I clinical trials.
LBS-008 received both US and EU orphan drug designation in 2017 and 2018, respectively.
Stargardt Disease is an untreatable inherited condition that causes permanent vision loss in children during childhood and adolescence.
This rare disease is caused by a mutation in the ABCA4 gene, which leads to the accelerated formation and accumulation of toxic vitamin A dimers in the retina that cause progressive retinal cell death and permanent loss of vision.
Lin BioScience, Inc. is a drug development company targeting untreatable diseases. Its therapeutic pipeline, which includes two candidates with Orphan Drug Status, is focused on meeting the unmet needs of patients suffering from cancer, macular degeneration, liver disease and diabetes.
Abilita Bio signs multi-target collaboration with Amgen
Innovent treats first cancer patient in Phase I clinical trial of Anti-OX40 Antibody
Parexel Appoints Former FDA Senior Executives to Global Regulatory Consulting Services
Omeros Names Bumol to Board of Directors
Bicycle Therapeutics Awarded GBP 496,000 SBRI Contract to Address Antimicrobial Resistance in Humans
Altasciences Launches New Brand and Website
Synlogic Names Patricia Hurter to Board of Directors
Calliditas Therapeutics announces grant of ODD by US FDA for primary biliary cholangitis